Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Launched by UNIVERSITY OF MIAMI · Feb 16, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the services and programs offered by the Leukemia and Lymphoma Society (LLS) affect patients with blood cancers like leukemia, lymphoma, and myeloma. The goal is to understand how these services help patients with things like getting medical care, improving their quality of life, and managing financial challenges.
To be eligible for this trial, participants should be currently receiving treatment for their blood cancer and have at least one unmet need that the LLS can help with, such as needing a second opinion or help with travel for treatment. Participants should be willing to be followed for six months and must speak either English or Spanish. Those who join can expect support from LLS, and their experiences will be used to help improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Be currently receiving primary or relapse treatment for a diagnosis of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN)
- • Report experiencing at least one unmet need addressed by the LLS Program (i.e., medical care including second opinions, travel for care, clinical trial access, financial and insurance needs, supportive programs, disease and treatment education)
- • Not be currently participating in any LLS programs or services
- • Be willing to be followed for 6 months
- • Speak English or Spanish
- Exclusion Criteria:
- • Are not receiving primary or relapse treatment for a diagnosis of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN)
- • Are not experiencing unmet needs addressed by the LLS Program (i.e., medical care including second opinions, travel for care, clinical trial access, financial and insurance needs, supportive programs, disease and treatment education)
- • Are currently participating in any LLS programs or services
- • Are not willing to be followed for 6 months
- • Do not speak English or Spanish.
About University Of Miami
The University of Miami, a leading academic institution, is dedicated to advancing medical research and improving patient care through innovative clinical trials. With a commitment to excellence in education and research, the university fosters collaboration among multidisciplinary teams to explore new therapies and treatment modalities. Its extensive clinical programs are supported by state-of-the-art facilities and a diverse patient population, enabling the exploration of cutting-edge solutions to complex health challenges. The University of Miami is poised to contribute significantly to the field of medicine through its rigorous scientific inquiry and a steadfast commitment to ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Miami, Florida, United States
San Antonio, Texas, United States
Patients applied
Trial Officials
Frank Penedo, PhD
Principal Investigator
University of Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials